P2-139: Targeted inhibition of wild type and mutated MET receptor variants in the sema, juxtamembrane and kinase domain  by Jiang, Shan et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS546
Improved efﬁcacy of targeted kinase inhibitors may be achieved by 
targeting the dominant activating mutations present.
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Background: MET belongs to the semaphorin superfamily of signaling 
proteins, containing three protein families (semaphorins, plexins, MET 
and RON) that have central roles in cell signaling. The MET receptor 
tyrosine kinase is involved in regulating cell growth/proliferation, sur-
vival, angiogenesis, cell scattering, cell motility and migration. Muta-
tions in MET have been identiﬁed in various human cancers including 
lung cancer and papillary renal cell carcinomas. MET mutations occur 
within the extracellular seven-blade β-propeller fold sema domain 
(E168D, L229F, S325G, N375S), the juxtamembrane domain (R988C, 
T1010I), and the kinase domain (M1268T). We hypothesized that these 
mutations would have differential effects on the kinase inhibition.
Methods: We modeled the various MET mutations from different 
functional domains of the receptor using Cos-7 transfection cell system 
to determine their effect on MET signaling and sensitivity to a selec-
tive MET kinase inhibitor SU11274. Sensitivity to SU11274 inhibi-
tion was assayed by phospho-immunoblotting using phospho-speciﬁc 
antibody against the major tyrosine kinase phosphorylation epitopes 
pY1234/1235 of the MET kinase in vitro.
Results: First, we identiﬁed that mutations in the sema and juxta-
membrane domain were activating as deﬁned by ligand-independent 
constitutive receptor activation. SU11274 was capable of inhibiting 
ligand induced signaling through the wild-type MET as well as mutant 
MET receptors harboring mutations in the sema, juxtamembrane and 
tyrosine kinase domain. However, SU11274 inhibition of mutant MET 
was mutation-dependent, with the juxtamembrane domain mutations 
R988C and T1010I resulting in a receptor form that was less sensitive 
to SU11274. Mutations in the sema and kinase domain also resulted 
in varying sensitivity to inhibition by SU11274 inhibition. Interest-
ingly, the kinase domain L1243R mutation in MET (homologous to the 
epidermal growth factor receptor L858R-EGFR sensitizing muta-
tion in lung cancer) substantially sensitized the mutant MET receptor 
to SU11274 inhibition with complete p-MET inhibition at 0.5 μM 
compared to 5 μM as in wild type. On the other hand, the activating 
M1268T mutation in the kinase domain was less sensitive to SU11274 
than the wild type receptor.
Conclusion: Mutations in the sema and juxtamembrane domain 
of MET result in receptor activation. The small molecule inhibi-
tor SU11274 is active against wild type and various mutated MET 
receptor. Further studies to characterize the signaling effects and the 
mechanism of sensitivity and resistance of MET mutations to speciﬁc 
inhibitors are crucial in the successful development of therapeutic MET 
inhibitors in personalized cancer therapy.
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Introduction: One of the basic exogenous factors of lung cancer 
incidence is smoking. On the other hand, hereditary predisposition in 
particular, genetic polymorphism of enzymes, plays an important part 
in development of oncologic diseases. The important role in oncopath-
ology emergence is assigned to glutathiontransferases (GST), because 
these enzymes are involved in detoxication of reactive metabolites. 
Mutations in detoxication genes are also known to be accompanied by 
the change in the cytogenetic parameter level, which are attributed to 
cytogenetic markers of early carcinogenesis stages. 
The interrelation between GSTT1 polymorphism and the chromosome 
aberrations level was analyzed in peripheral blood lymphocytes (PBL) 
and lung tissues of non-small-celled lung cancer (NSCLC) patients.
Materials and Methods: The frequencies of GSTT1 gene polymor-
phic alleles were investigated using a polymerase chain reaction in 49 
NSCLC patients. 
For cytogenetic research the interphase analysis of somatic cells 
without cultivation was used. The frequency of cells with micronuclei 
was estimated in PBL and in lung cells from nontumour tissues of lung 
cancer patients.
Results and Discussion: Analysis of GSTT1-gene polymorphism has 
shown that GSTT1(-) genotype occurred signiﬁcantly more often in 
NSCLC patients (26,6%) than in the control (4%). The study on genetic 
GSTT1 polymorphism with due account of the smoking factor has 
demonstrated that the GSTT1(-) genotype was observed with statistical 
signiﬁcance 1,5-fold more often (36,4%) in the group of non-smoking 
patients than among smoking ones - 23,7%. It is interesting that such 
regularity was revealed by other researchers for many others genes of 
xenobiotic biotransformation enzymes. 
The obtained data of the cytogenetic analysis in different tissues 
of oncologic patients were estimated by us with due account of the 
smoking factor and the genotype. In non-smoking patients, the level 
of cells with micronuclei in PBL was twice as high in the patients 
with the GSTT1(+) genotype (0,43±0,13%) as in the patients with the 
GSTT1(-) genotype (0,21±0,07%). In smoking patients the level of 
cells with micronuclei in PBL did not differ signiﬁcantly in carriers 
of the GSTT1(+) genotype (0,32±0,05%) and the GSTT1(-) genotype 
(0,29±0,09%). Some authors associate the low number cells with chro-
mosome aberrations in smoking patients and GSTT1 (-) carriers with 
higher enzyme expression, involved in repair of DNA damages.
Statistically signiﬁcant excess of the group average level of cells with 
micronuclei was shown in nontumoral tissue of smoking patients 
with the GSTT1(-) (0,57±0,08%) over those with the GSTT1(+) 
(0,33±0,04%). In non-smoking patients, the level of cells with 
micronuclei did not differ in GSTT1(-) - 0,30±0,02% and GSTT1(+)- 
0,38±0,14%. Damaging effect of tobacco smoke carcinogens directly 
on lung tissue in smokers is one of explanations of this fact that in 
combination with availability of mutant gene alleles of detoxication 
enzymes results in high probability of emerging cytogenetic injuries 
just in lung tissue. 
